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Impact of High-Dose Statin Pretreatment in Patients with Stable 
Angina during Off-Pump Coronary Artery Bypass
Young-Nam  Youn,  M.D.*,  Seong-Yong  Park,  M.D.*,  Yoohwa  Hwang,  M.D.*, 
Huyn-Chul  Joo,  M.D.*,  Kyung-Jong  Yoo,  M.D.*
Background:  Periprocedural treatment with high-dose statins is known to have cardioprotective and pleiotropic ef-
fects, such as anti-thrombotic and anti-inflammatory actions. We aimed to assess the efficacy of high-dose rosuvas-
tatin loading in patients with stable angina undergoing off-pump coronary artery bypass grafting (OPCAB). Materials 
and Methods: A total of 142 patients with stable angina who were scheduled to undergo surgical myocardial re-
vascularization were randomized to receive either pre-treatment with 60-mg rosuvastatin (rosuvastatin group, n=71) 
or no pre-treatment (control group, n=71) before OPCAB. The primary endpoint was the 30-day incidence of major 
adverse cardiac events (MACEs). The secondary endpoint was the change in the degree of myocardial ischemia 
as evaluated with creatine kinase-myocardial band (CK-MB) and troponin T (TnT). Results: There were no sig-
nificant intergroup differences in preoperative risk factors or operative strategy. MACEs within 30 days after OPCAB 
occurred in one patient (1.4%) in the rosuvastatin group and four patients (5.6%) in the control group, respectively 
(p=0.37). Preoperative CK-MB and TnT were not different between the groups. After OPCAB, the mean maximum 
CK-MB was significantly higher in the control group (rosuvastatin group 10.7±9.75 ng/mL, control group 14.6±12.9 
ng/mL, p=0.04). Furthermore, the mean levels of maximum TnT were significantly higher in the control group 
(rosuvastatin group 0.18±0.16 ng/mL, control group 0.39±0.70 ng/mL, p=0.02). Conclusion: Our findings suggest 
that high-dose rosuvastatin loading before OPCAB surgery did not result in a significant reduction of 30-day 
MACEs. However, high-dose rosuvastatin reduced myocardial ischemia after OPCAB.
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INTRODUCTION
    Reduction  of  plasma  cholesterol,  particularly  cholesterol 
transported in low-density lipoproteins (LDL), lowers the risk 
of  primary  and  secondary  cardiovascular  events.  3-hy-
droxy-3-methylglutaryl (HMG)-CoA reductase inhibitors, com-
monly known as statins, can produce significant reductions in 
cholesterol.  It  is  well  known  that  the  beneficial  effect  of  sta-
tins on coronary events is related to their hypocholesterolemic 
properties. However, the immediate product of HMG-CoA re-
ductase, mevalonic acid, is not only a substrate for cholester-
ol synthesis but also a precursor of isoprenoids and other me-High-Dose Statin before OPCAB
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tabolites  involved  in  different  cellular  pathways  of  athero-
genesis  and  thrombosis  [1].  As  a  consequence,  statins  may 
result in pleiotropic effects that are independent of cholesterol 
reduction,  which  may  explain  many  of  the  direct  anti-athero-
sclerotic  and  anti-thrombotic  properties  of  these  compounds 
[1-6].
    The  ARMYDA  (Atorvastatin  for  Reduction  of  Myocardial 
Damage During Angioplasty) trial [7] has shown that a 7-day 
pretreatment  with  atorvastatin  is  associated  with  an  81%  re-
duction  in  the  risk  of  periprocedural  myocardial  infarction  in 
patients  with  stable  angina  undergoing  elective  percutaneous 
coronary intervention (PCI). Attenuation of endothelial activa-
tion  may  explain  this  protective  role  at  least  in  part  [8],  and 
preprocedural  loading  with  atorvastatin  may  even  improve 
outcomes  in  patients  with  acute  coronary  syndrome  under-
going  early  invasive  intervention  [9].
    Recently,  statins  were  shown  to  be  independently  asso-
ciated  with  a  reduced  risk  of  postoperative  mortality  in  pa-
tients  undergoing  major,  noncardiac  vascular  surgery  [10]. 
Furthermore,  preoperative  s t a t i n  t h e r a p y  h a s  b e e n  i n -
dependently associated with a significant reduction in the risk 
o f  a l l - c a u s e  m o r t a l i t y  i n  p a t i e n ts  undergoing  coronary  artery 
bypass  grafting  (CABG)  surgery  [11-13].  However,  patients 
were treated with different types of statins and variable doses, 
and  the  duration  of  previous  treatment  was  unknown. 
Additionally,  these  findings  have  not  been  validated  in  a 
randomized trial, and most patients in these studies underwent 
CABG  using  cardiopulmonary  bypass. 
    Avoiding  the  systemic  inflammatory  response  that  may  re-
sult  from  cardiopulmonary  bypass,  off-pump  coronary  bypass 
grafting  (OPCAB)  is  known  to  have  benefits  in  high-risk 
patients.  The  anti-inflammatory  and  pleiotropic  effects  of  sta-
tins  and  their  effects  on  clinical  outcomes  for  patients  who 
undergo the  OPCAB  procedure  have  not  been  described. The 
aim  of  the  current  study  was  to  determine  whether  pre-
operative  rosuvastatin  loading  is  independently  associated 
with  reduced  myocardial  ischemia  and  clinical  outcomes  in 
patients  with  stable  angina  undergoing  isolated  OPCAB.
MATERIALS AND METHODS
1) Study population and design
    This  trial  was a  single-center,  randomized, prospective  trial 
performed at our hospital. Inclusion criteria were the presence 
of  stable  angina,  age  between  18  and  80  years,  and  a  need 
for  isolated  surgical  myocardial  revascularization.  Exclusion 
criteria were evidence of recent myocardial infarction and un-
stable  angina,  emergent  or  urgent  operation,  history  of  prior 
cardiac  surgery,  any  increase  in  liver  enzymes,  renal  failure 
with  serum  creatinine  ＞3  mg/dL,  left  ventricular  ejection 
fraction ＜35%, and  history of liver or muscle disease.  From 
October 2007 to December 2008, a total of 214 patients who 
met  the  inclusion  criteria  were  initially  evaluated;  7  patients 
were excluded because of previous cardiac surgery, 15 for in-
creased liver enzymes, 16 for renal failure with creatinine >3 
mg/dL, 19 for low ejection fraction, 5 for history of liver dis-
ease,  and  10  for  refusal  to  participate  in  the  study.  Eligible 
patients  (n=142)  were  randomized  to  receive  rosuvastatin  (40 
mg  loading  dose  12  hours  before  surgery  and  a  second  20 
mg  dose  2  hours  before  surgery)  or  no  pretreatment  (control 
group).  Patients  were  assigned  in  a  1 : 1  ratio  using  a  com-
puter-generated  randomization  sequence.  This  study  protocol 
was  approved  by  the  Institutional  Review  Board  of  Yonsei 
University College of Medicine and individual patient consent 
was  obtained.
2) Operative technique 
    We  have  previously  described  the  operative  technique  and 
graft strategy [14,15]. The operation was performed through a 
full  sternotomy  incision  or  minimal  incision  through  the  left 
fifth  intercostal  space,  and  the  left  internal  mammary  artery 
was  harvested  in  a  semi-skeletonized  fashion.  The  second 
choice  of  graft  was  the  radial  artery,  which  was  harvested 
with a harmonic scalpel (Ethicon Endosurgery Inc., Cincinna-
ti,  OH).  The  right  internal  mammary  artery,  saphenous  vein, 
or  right  gastroepiploic  artery  was  also  harvested  if  necessary. 
Heparin  (0.7∼1.0  mg/kg)  was  administered  to  achieve  a  tar-
get  activated  clotting  time  (≥300  seconds)  before  ligation  of 
the distal internal mammary artery. Target arteries were stabi-
lized  with  a  tissue  stabilizer  and  heart  positioner.  During 
anastomosis,  blood  was  removed  from  the  arteriotomy  sites Young-Nam Youn, et al
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Table 1. Demographics and baseline clinical characteristics
　
Rosuvastatin 
group
Control 
group
p-value
Female 
Age,  yrs 
Smoker 
Diabetes  mellitus 
Hypertension 
Dyslipidemia 
Chronic  statin  treatment 
Chronic  renal  failure
CVA  history 
PAOD 
Previous  PTCA 
Preoperative  medication 
    Beta  blocker 
    ACE  inhibitor
    IV  Nitrate 
  A R B
Old  myocardial  infarction
Three  vessel  disease
Left  main  disease
Ejection  fraction  (%) 
EuroSCORE 
14  (19.7)
65.9±8.6
34  (47.9)
28  (39.4)
52  (73.2)
20  (28.2)
39  (54.9)
 9  ( 1 2 . 7 )
 9  ( 1 2 . 7 )
 8  ( 1 1 . 3 )
10  (14.1)
51  (71.8)
7  (9.9)
22  (31)
21  (29.6)
21  (29.6)
58  (81.7)
24  (33.8)
59.6±13.8
3.1±2.2
18  (25.4)
66.6±7.6
39  (54.9)
31  (43.7)
54  (76.1)
20  (28.2)
39  (54.9)
6  (8.5)
4  (5.6)
2  (2.8)
  9  (12.7)
48  (67.6)
  9  (12.7)
17  (23.9)
22  (31)
23  (32.4)
63  (88.7)
21  (29.6)
59.5±16.0
3.3±2.1
0.42 
0.62
0.40 
0.61 
0.70 
1.00 
1.00 
0.41 
0.24 
0.10 
0.81 
0.58 
0.60 
0.35 
0.86 
0.72 
0.43 
0.59 
0.95 
0.53 
CVA=Cerebrovascular  accident;  PAOD=Peripheral  artery  obstr-
uctive  disease;  PTCA=Percutaneous  transluminal  coronary  angi-
oplasty;  ACE=Angiotensin  converting  enzyme;  IV=Intravenous; 
ARB=Angiotensin  II  receptor  blocker;  EuroSCORE=European 
system  for  cardiac  operative  risk  evaluation.
with  a  misted  carbon  dioxide  blower  and  irrigation  with 
warm  saline.  After  surgery,  patients  were  transferred  to  the 
intensive  care  unit  and  managed  as  usual.
3) Cardiac enzyme assay
    In  all  patients,  blood  samples  were  collected  before 
OPCAB  and  at  24,  48,  and  72  hours  after  OPCAB  to  de-
termine  the  levels  of  creatine  kinase-myocardial  band 
(CK-MB)  isoenzyme  and  troponin-T.  Normal  limits  of 
CK-MB  and  troponin  T  were  defined  as  ≤5  ng/mL  and 
＜0.1 μg/L,  respectively. 
4) Data collection and definition of terms
    Preoperative,  intraoperative,  and  postoperative  data  were 
collected  prospectively  from  the  registry  database,  medical 
notes, and medical charts. Detailed data were collected on the 
admission when cardiac surgery was performed. Complete re-
vascularization  was  defined  as  the  placement  of  at  least  one 
graft  onto  each  of  the  three  major  vascular  regions  that  ex-
hibited  stenosis  of  more  than  50%  of  diameter  [16,17]. 
Perioperative  MI  was  defined  as  an  increase  in  biomarkers 
greater than 5 times the 99th percentile of the upper reference 
limit  (URL)  plus  one  of  the  following:  either  new  patho-
logical  Q  waves  or  new  LBBB,  angiographically  documented 
new graft or native coronary artery occlusion, or imaging evi-
dence of new loss of viable myocardium [18]. Other variables 
were  defined  according  to  the  Society  of  Thoracic  Surgeons 
Adult  Cardiac  Database  Definition  of  Terms  version  2.61 
(http://www.sts.org/documents/pdf/AdultCVDataSpecifications2. 
61.pdf). 
5) Endpoints
    The primary endpoint was the occurrence of major adverse 
cardiac events (MACEs), which included the following: death 
from  all  causes,  non-fatal  myocardial  infarction  (MI),  and  re-
peat  revascularization  by  percutaneous  intervention  or  bypass 
surgery  within  30  days  after  the  operation.  The  secondary 
endpoint  was  the  difference  in  the  degree  of  myocardial  is-
chemia between the two groups after OPCAB. The degree of 
myocardial  ischemia  was  measured  by  the  highest  level  of 
cardiac  enzymes  after  OPCAB. 
6) Statistical analysis
    Categorical  variables  were  expressed  as  mean±standard  de-
viation (SD). Categorical variables were compared by χ
2 test 
or Fisher’s exact test. A Student’s t-test was used to compare 
continuous  variables  for  normal  distribution;  otherwise,  the 
Mann-Whitney  U  test  was  used.  Data  were  analyzed  using 
SPSS  for  Windows,  version  15.0  (SPSS,  Inc,  Chicago,  IL). 
p-values equal to or less than 0.05 indicated a significant dif-
ference,  and  all  p-values  were  two-tailed.
RESULTS
    Seventy-one  patients  were  allocated  to  each  group.  Patient 
demographics  and  baseline  clinical  characteristics  are  dis-
played in Table 1. The two groups were similar in regards to 
the  following:  age;  prevalence  of  females;  smoking  status; High-Dose Statin before OPCAB
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Table 2. Operative data
　
Rosuvastatin 
group
Control 
group
p-value
Operation  time  (min) 
Distal  anastomosis 
Total  arterial  grafting
Use  of  LITA
Complete  revasculazation 
235.3±39.9
3.2±0.8
37  (52.1)
70  (98.6)
71  (100)
240.5±39.6
3.1±0.8
44  (62.0)
69  (97.2)
69  (97.2)
0.34
0.4
0.24
1.00 
0.5
LITA=Left  internal  thoracic  artery.
Table 3. Incidence of the primary endpoint
　
Rosuvastatin 
group
Control 
group
p-value
30-day  MACEs
Death
Nonfatal  MI
Target  vessel 
  revascularization
1  (1.4)
0
0
1  (1.4)
4  (5.6)
1  (1.4)
3  (4.2)
0
0.37
1
0.25
1
MACEs=Major  adverse  cardiac  events;  MI=Myocardial  infarc-
tion.
Fig. 1. Changes in cardiac enzymes after operation. (A) Change in the level of CK-MB. (B) Change in the level of troponin T. 
Preop=Preoperative level (white bar); Highest=Highest level at postoperative period (gray bar). *=p-value＜0.05.
prevalence  of  diabetes  mellitus,  hypertension,  dyslipidemia 
chronic  renal  failure,  and  peripheral  arterial  obstructive  dis-
ease;  chronic  statin  treatment  for  more  than  one  month;  his-
tory  of  cerebrovascular  accidents  and  percutaneous  trans-
luminal coronary angioplasty; medication use; degree of coro-
nary  artery  disease;  and  left  ventricular  ejection  fraction. 
Preoperative  risk,  as  assessed  by  EuroSCORE,  was  not  sig-
nificantly  different  between  the  groups  (rosuvastatin  group 
3.1±2.2,  control  group  3.3±2.1,  p=0.53).  There  were  no  sig-
nificant  differences  in  the  duration  of  the  operation,  number 
of  distal  anastomosis,  total  arterial  grafting,  or  complete  re-
vascularization  (Table  2).
  T h e  p r i m a r y  e n d p o i n t  w a s  e v a l u a t e d  a t  3 0  d a y s  ( T a b l e  3 ) .  
The  composite  primary  endpoint  of  death,  myocardial  in-
farction,  and  target  vessel  revascularization  occurred  in  3.5% 
o f  p a t i e n t s  ( 5  o f  1 4 2 ) ,  o n e  p a t i e nt  (1.4%)  in  the  rosuvastatin 
group  and  four  patients  (5.6%)  in  the  control  group.  No  sig-
nificant  difference  was  found  between  groups  in  overall 
(p=0.37) or individual cardiac events. One patient with chron-
i c  r e n a l  f a i l u r e  d i e d  i n  t h e  c o n t r o l  g r o u p  d u e  t o  t h e  a g -
gravation  of  renal  and  respiratory  failure.
    Changes  in  cardiac  enzymes  are  displayed  in  Fig.  1. 
Preoperative  CK-MB  and  troponin  T  were  not  different  be-
tween  groups  (CK-MB,  rosuvastatin  group  2.15±0.85  ng/mL, 
control  group  1.99±0.76  ng/mL,  p=0.24;  troponin  T,  rosuvas-
t a t i n  g r o u p  0 . 0 3 ±0.07  ng/mL,  control  group  0.03±0.09 
ng/mL,  p=0.52).  After  OPCAB,  the  mean  maximum  CK-MB 
was  significantly  higher  in  the  control  group  (rosuvastatin 
group  10.7±9.75  ng/mL,  control  group  14.6±12.9  ng/mL, 
p=0.04). Furthermore, the levels of the mean maximum tropo-
nin  T  were  significantly  higher  in  the  control  group 
(rosuvastatin  group  0.18±0.16  ng/mL,  control  group Young-Nam Youn, et al
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0.39±0.70 ng/mL, p=0.02). In the rosuvastatin group, CK-MB 
decreased  by  26.7%  and  troponin  T  decreased  by  53.8% 
compared  to  the  control  group.
DISCUSSION
    This  study  is  the  first  single-center  randomized  trial  to 
evaluate  the  efficacy  of  high-dose  rosuvastatin  loading  (60 
mg)  before  OPCAB  in  patients  with  stable  angina.  At  the 
1-month  clinical  follow-up  assessment,  the  occurrence  of  ma-
jor  cardiac  events  was  not  significantly  different  between  the 
control and 60-mg rosuvastatin pretreatment groups. However, 
our  study  suggests  that  high-dose  rosuvastatin  loading  before 
OPCAB  may  decrease  myocardial  ischemia  as  determined  by 
CK-MB  and  troponin  T  after  OPCAB.
    The  benefit  of  periprocedural  treatment  with  statins  in 
on-pump  CABG is  well  established.  In the Multicenter Study 
of  Perioperative  Ischemia  (McSPI)  Epidemiology  II  Study 
[13], the authors reported that preoperative statin therapy was 
independently  associated  with  a  significant  reduction  in  the 
risk of early cardiac death after elective on-pump CABG, but 
was  not  associated  with  a  reduced  risk  of  postoperative  non-
fatal,  in-hospital  MI.  Powell  et  al.  [19]  evaluated  the  influ-
ence  of  lipid-lowering  therapy  for  30  days  before  CABG.  In 
this  observational  study  with  4,739  patients,  in-hospital  mor-
tality  was  significantly  lower  in  the  lipid-lowering  therapy 
group  than  in  the  nonlipid-lowering  therapy  group  (1.4%  vs. 
2.2%,  odds  ratio  0.62,  95%  CI  0.40∼0.96,  p=0.03).  Even 
though  the  multivariable  model  demonstrated  a  loss  of  stat-
istical  significance  for  the  effect  of  lipid-lowering  therapy  on 
in-hospital  mortality,  they  suggested  that  patient  risk  factors 
and  the  use  of  other  cardioprotective  medications  associated 
w i t h  t h e  u s e  o f  p r e o p e r a t i v e  l i pid-lowering  therapy  appeared 
to  explain  the  association  with  improved  survival.  Several 
prospective  trials  have  been  conducted  to  validate  these  find-
ings of statin pre-treatment in PCI and CABG settings. In the 
ARMYDA-ACS  trial  [9],  short-term  atorvastatin  loading  con-
ferred  an  88%  risk  reduction  in  30-day  MACEs  in  patients 
with  acute  coronary  syndrome  before  PCI.  Mannacio  et  al. 
evaluated  the  effect  of  20  mg/d  rosuvastatin  pretreatment  for 
1  week  before  on-pump  CABG.  Troponin  I,  myoglobin,  and 
CK-MB  mass  values  were  assessed,  and  all  biological  mark-
ers  were  significantly  lower  in t h e  r o s u v a s t a t i n  p r e t r e a t m e n t  
group.  However,  few  studies  have  evaluated  statin  pretreat-
ment  in  OPCAB  patients.  Song  et  al.  [20]  reported  that  pre-
operative loading with atorvastatin for 3 days before OPCAB 
significantly  reduced  the  occurrence  of  postoperative  atrial 
fibrillation.
    A  total  of  60  mg  rosuvastatin  was  loaded  before  OPCAB 
in  this  study.  According  to  a  well-reviewed  paper  [21]  about 
pre-procedural  statin  therapy,  the  loading  dosages  of  various 
statins  before  PCI  or  CABG  were  mostly  determined  by 
researchers.  In  our  preliminary  study,  40  mg  rosuvastatin 
loading  12  hours  before  OPCAB  did  not  result  in  significant 
decreases  of  cardiac  enzymes  and  inflammatory  markers.  20 
mg  of  rosuvastatin  were  added  2  hours  before  OPCAB,  and 
no  serious  side  effects  of  60  mg  rosuvastatin  loading  were 
found.
    This  study  found  no  significant  reduction  in  30-day 
MACEs. The effects of high-dose rosuvastatin loading in this 
study  could  not  be  determined  because  the  incidence  of  clin-
ical  events  was  low  in  both  patient  groups.  However,  there 
was a tendency toward a lower number of MACEs in the ro-
suvastatin loading group and further study with more patients 
is  warranted.
    In  this  study,  statin  loading  before  OPCAB  significantly 
lowered  the  degree  of  myocardial  ischemia  as  assessed  by 
cardiac  enzymes.  Although  these  beneficial  effects  of  statin 
loading  on  myocardial  protection  cannot  be  completely  ex-
plained, this early protective effect of statins is unlikely to be 
the  result  of  its  effect  on  cholesterol.  Instead,  statins  exert 
pleiotropic  effects  that  may  be  initiated  before  its  lipid-low-
ering  effects  [22].  Previous  studies  show  the  improvement  of 
myocardial  ischemia  after  OPCAB  that  we  observed  in  this 
study.  Protection  from  aggravation  of  myocardial  ischemia 
may result  from the  pleiotropic effects  of statins, such as  the 
improvement  of  endothelial  function,  dilatation  of  coronary 
microvessels,  anti-thrombotic  ef f e c t s ,  a n d  a n t i - inflammatory 
action  [23,24]. 
  Our study had several limitations. First, two surgeons from 
a  single center conducted the  trial. Second, myocardial ische-
mia  was  only  assessed  by  CK-MB  and  troponin  T,  which 
may  have  lower  specificity  in  certain  conditions,  such  as  re-
nal  dysfunction.  Third,  sample  size  was  relatively  small  with High-Dose Statin before OPCAB
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low  clinical  morbidity  and  mortality,  and  accordingly,  a  stat-
istical  difference  may  not  have  been  detected.  These  factors 
should  be  addressed  using  larger  cohorts  in  multicenter  trials 
that  evaluate  the  effects  of  statin  loading  before  OPCAB 
surgery. 
CONCLUSION
    Our  findings  suggest  that  high-dose  rosuvastatin  loading 
before  OPCAB  surgery  did  not  result  in  a  significant  reduc-
tion  of  30-day  MACEs.  However,  high-dose  rosuvastatin  re-
duced  myocardial  ischemia  after  OPCAB.   
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